Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. | Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. | Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | |
Founding Date | Founding Date 2004 | Founding Date 2002 | Founding Date 2006 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US | Locations San Diego, US HQ San Diego, US | ||
Employees | Employees 1386% increase | Employees 1,32324% increase | Employees 31019% decrease | Employees 5,60044% increase |
Valuation ($) | Valuation ($) 778.3 k | Valuation ($) 33.6 b | Valuation ($) 3.3 m | Valuation ($) 26.8 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $1.5m (FY, 2022) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $6.8b (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods $4.7b (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit $2.2b (FY, 2023) |
Net income | Net income ($25m) (FY, 2022) | Net income ($440.2m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income ($4.7b) (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised $ 1.8b |